1. Home
  2. TSBX vs IMRN Comparison

TSBX vs IMRN Comparison

Compare TSBX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSBX
  • IMRN
  • Stock Information
  • Founded
  • TSBX 2015
  • IMRN 1994
  • Country
  • TSBX United States
  • IMRN Australia
  • Employees
  • TSBX N/A
  • IMRN N/A
  • Industry
  • TSBX
  • IMRN Biotechnology: Pharmaceutical Preparations
  • Sector
  • TSBX
  • IMRN Health Care
  • Exchange
  • TSBX Nasdaq
  • IMRN Nasdaq
  • Market Cap
  • TSBX 7.7M
  • IMRN 9.2M
  • IPO Year
  • TSBX 2023
  • IMRN N/A
  • Fundamental
  • Price
  • TSBX $0.37
  • IMRN N/A
  • Analyst Decision
  • TSBX Buy
  • IMRN Strong Buy
  • Analyst Count
  • TSBX 3
  • IMRN 1
  • Target Price
  • TSBX $4.75
  • IMRN $5.00
  • AVG Volume (30 Days)
  • TSBX 481.7K
  • IMRN 24.6K
  • Earning Date
  • TSBX 08-13-2025
  • IMRN 07-15-2025
  • Dividend Yield
  • TSBX N/A
  • IMRN N/A
  • EPS Growth
  • TSBX N/A
  • IMRN N/A
  • EPS
  • TSBX N/A
  • IMRN N/A
  • Revenue
  • TSBX N/A
  • IMRN $4,048,286.00
  • Revenue This Year
  • TSBX N/A
  • IMRN N/A
  • Revenue Next Year
  • TSBX N/A
  • IMRN N/A
  • P/E Ratio
  • TSBX N/A
  • IMRN N/A
  • Revenue Growth
  • TSBX N/A
  • IMRN 82.90
  • 52 Week Low
  • TSBX $0.29
  • IMRN $1.50
  • 52 Week High
  • TSBX $2.69
  • IMRN $2.87
  • Technical
  • Relative Strength Index (RSI)
  • TSBX 52.32
  • IMRN 49.46
  • Support Level
  • TSBX $0.33
  • IMRN $1.56
  • Resistance Level
  • TSBX $0.37
  • IMRN $1.96
  • Average True Range (ATR)
  • TSBX 0.03
  • IMRN 0.11
  • MACD
  • TSBX -0.00
  • IMRN -0.01
  • Stochastic Oscillator
  • TSBX 53.33
  • IMRN 53.75

About TSBX Turnstone Biologics Corp.

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Share on Social Networks: